Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has recently completed a clinical study titled ...

Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...

Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia ...

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated ...

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase 3b, multicenter, ...

Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...

Despite clear NCCN guidelines for frontline chronic lymphocytic leukemia (CLL) therapies, significant racial and ethnic ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...